GET LIVE MARKET QUOTES & NEWS
Download App
Moneycontrol
HomeNewscoronavirus

76 samples of new Covid variant XBB1.16 found in India: INSACOG data

PTI
Mar 18, 2023 / 02:57 PM IST

The XBB 1.16 variant was first found in January when two samples tested positive for the variant while in February a total of 59 samples were found.

A total of 76 samples of COVID-19's XBB.1.16 variant have been found which might be behind the recent rise of cases in the country, according to INSACOG data.

The variant has been found across Karnataka (30), Maharashtra (29), Puducherry (7) Delhi (5), Telangana (2), Gujarat (1), Himachal Pradesh (1) and Odisha (1), the Indian SARS-CoV-2 Genomics Consortium (INSACOG) data showed.

The XBB 1.16 variant was first found in January when two samples tested positive for the variant while in February a total of 59 samples were found. In March, till now 15 samples of the XBB 1.16 variant have been found, the INSACOG said.

Some experts have attributed the recent rise in COVID-19 cases to this variant. Former AIIMS director Dr Randeep Guleria, who had led the national Covid task force, said the rise in Covid cases seems to be driven by the XBB 1.16 variant while the influenza cases are because of H3N2.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
 View more
+ Show